PP-111 Optimal threshold: baseline serum hepatitis B virus DNA and alanine transaminase levels predict the 2-year on-treatment virological response to lamivudine

Abstract

BackgroundHBV is still a worldwide health problem. Annually about 0.5-1.2 million patients die of HBV-related diseases such as liver cirrhosis and hepatocellular carcinoma. Lamivudine (LAM) is the first nucleoside analog used in the treatment of chronic hepatitis B. As LAM has been clinically used for a long time, increasing clinical experience has been achieved showing that the resistance mutation rate is relatively high. Numerous studies have also focused on the predictive factors of long-term efficacy of LAM treatment.ObjectivesTo determine the optimal cutoff values of baseline hepatitis B virus (HBV) DNA and alanine transaminase (ALT) levels as predictors for the long-term efficacy of LAM treatment in patients with chronic hepatitis B.Patients and MethodsA total of 163 HBeAg-positive chronic hepatitis B patients receiving LAM treatment were recruited into the present study. Logistic regression analysis was performed to find out the independent predictors of 2-year on-treatment virological response among the baseline parameters. The receiver operating characteristic (ROC) curve was used to evaluate the optimal cutoff values of these independent predictors. The accuracy of the prediction was assessed using the area under curve (AUC) and optimal cutoff values were determined through maximizing the Youden's index.ResultsAfter 2 years of LAM treatment, undetectable HBV DNA was maintained in 114 (69.9%) patients. LAM-related resistance mutation (YMDD mutation) was detected in 45 (27.6%) patients. Logistic regression analysis indicated that the baseline ALT and HBV DNA levels were the independent predictors of the efficacy. ROC curve analysis suggested the integration parameter derived from the baseline ALT and HBV DNA levels had the maximal predictive value for a 2-year on-treatment virological response. The optimal cutoff values of ALT and HBV DNA were 220 IU/L and 8.2 log10 copies/mL, respectively.ConclusionsThe incidence of LAM-resistant mutations in HBeAg-positive chronic hepatitis B patients may be significantly reduced and long-term efficacy improved when the baseline ALT was greater than 220 IU/L and HBV DNA was less than 8.2 log10 copies/mL.

A model with combined viral and metabolic factors effectively predicts HBeAg status under long term entecavir therapy: a prospective cohort study

“…Apart from two factors mentioned above, relatively lower HBV DNA levels (<10 7 copies/ml) at baseline were independently associated with a stepwise increasing rate for the HBeAg seroconversion. A same finding was observed in previous studies [ 34 ]. Consistently, HBeAg seroconversion in patients treated with LDT can be predicted by baseline HBV DNA and ALT levels [ 35 ].…”

Relapse Rate and Associated-Factor of Recurrence after Stopping NUCs Therapy with Different Prolonged Consolidation Therapy in HBeAg Positive CHB Patients

“…Yan et al [22] approves that long-term efficacy of LAM is improved if the baseline ALT is more than 220 U/L. In the present study, we found that ALT level at baseline was associated with HBV recurrence after off-therapy and the cumulative rate of relapse was decreased if the baseline ALT was more than 80 U/L.…”

Association Analysis between SNPs in IL-28B Gene and the Progress of Hepatitis B Infection in Han Chinese

“…Globally, Hepatitis B virus (HBV) is the most frequent underlying cause of HCC. In hyper-epidemic areas such as China and Africa, chronic HBV infection contributes to at least 80% of cases of HCC[10]. There is intense interest in cellular and molecular mechanisms underlying HBV-associated HCC incidence.…”